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Successful treatment of pulmonary
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infection, in a patient with diabetes mellitus
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Although commonly found in our environment, somefungi are potentially pathogenic and may causediseases resembling pneumonia. These infectionsoccur mainly in human beings with various predis-
posing conditions. Pulmonary mucormycosis is uncommon but
is an acute and life-threatening disease. The disease can
progress from the acute phase to stages characterized by exac-
erbation and finally to end-stage septicemia.1-3 A diagnosis of
mucormycosis can usually be made at autopsy.
Clinical Summary
A 64-year-old man was admitted to hospital with the complaints of
nausea, chest pain, dyspnea, and general malaise. He gave a
history of heavy alcohol intake (4 U/d), excessive smoking (Brink-
man index 900), and poorly controlled diabetes mellitus.
Two weeks before admission, he had become nauseated and
started to have paroxysmal nocturnal dyspnea and night sweats. He
attended a private clinic, but the dyspnea and nausea became
increasingly troublesome, despite treatment with antibiotics and
antipyretics. Chest radiography revealed an area of consolidation
in the right lung, and pulmonary tuberculosis or lung cancer was
suspected. The patient was therefore transferred to our hospital for
further investigations.
Clinical examination revealed a thin man with wheezing res-
piration and mild pharyngitis. He was mildly pyrexial at 37.6°C,
and his blood pressure was 95/69 mm Hg. A 24-hour urine
collection had a volume of 5860 mL, contained 70.3 g glucose and
yielded a creatinine clearance of 67 mL/min.
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Liver function tests revealed total bilirubin of 60 mg/dL, an
alkaline phosphatase activity of 342 IU/L, an aspartate aminotrans-
ferase activity of 54 IU/L, and a -glutamyl transpeptidase activity
of 213 IU/L. The blood urea nitrogen level was 12.9 mg/dL, and
the blood glucose level was 301 mg/dL. Hematologic investiga-
tions showed hypochromic microcytic anemia with a hematocrit of
33.7% and a red blood cell count of 3,420,000 cells/mm3. The
white blood cell count was 3400 cells/mm3.
Chest radiographs (Figure 1, A) revealed nodular infiltration in
the right midzone. Chest computed tomographic scan (Figure 1, B)
demonstrated an opacity in the ventral segment of the upper lobe.
Pulmonary tuberculosis was suspected, but the patient’s sputum
and bronchoalveolar lavage specimens yielded negative results for
acid-fast bacilli on smear and after prolonged culture. A transbron-
chial lung biopsy was therefore performed in the inferior subseg-
ment of the right upper lobe. Transbronchial lung biopsy tissue
sections were stained with hematoxylin and eosin and exhibited an
inflammatory cell infiltrate, together with organisms that appeared
as broad, nonseptate hyphae (Figure 2). A diagnosis of pulmonary
mucormycosis was therefore made.
The patient’s general medical and nutritional condition was
poor, and it was considered that he could not face a surgical
resection. He therefore underwent bronchoscopy in the supine
position. After the administration of 5% lidocaine, the bron-
choscope was passed into the right main bronchus to reach the
area of infection. Radiographic monitoring of the bronchoscopy
Figure 1. Chest X-ray film (A) and computed tomographic scan (B) on admission, revealing round opacity in right
upper lobe. Chest computed tomographic scan (C) taken 6 months after start of therapy, revealing significant
reduction in opacity.
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was performed to ensure accurate positioning before the instil-
lation of 10 mL amphotericin B (Fungizone, 2 mg/mL) into the
lesion. This was repeated seven times during a 1-month period.
The patient was also treated with aerosolized amphotericin B (1
mL volume at 5 mg/mL administered twice daily by nebulizer)
and intravenous amphotericin B (25 mg on alternate days).
Blood sugar levels were controlled with insulin injections.
A repeated chest computed tomographic scan (Figure 1, C)
performed 6 months later revealed a significant reduction in opac-
ity at the same level, and the patient was subsequently discharged
from the hospital. He continued to receive the aerosolized ampho-
tericin B treatment at his home for 1 year and has made a complete
recovery.
Discussion
This patient had an opacity in his right lung develop during the
course of a flu-like prodromal illness. The clinical symptoms and
the chest radiographic abnormalities were highly suggestive of
pulmonary tuberculosis, but sputum and bronchoalveolar lavage
specimens were both smear and culture negative for mycobacteria.
Finally, transbronchial lung biopsy revealed a druse of Mucor, a
definitive diagnosis of pulmonary mucormycosis was made, and
treatment with amphotericin B was initiated.
To our knowledge, this is the first report of curative treatment
of pulmonary Mucorales by topical treatment alone.4 Mucormy-
cosis is currently a rare disease, but it is likely that patient numbers
will increase in the future in parallel with the increases in patients
with leukemia, diabetes, dialysis, immunodeficiency syndromes,
and transplants.5 Immunosuppressed transplant recipients should
be followed up carefully so that mycoses may be detected at an
early stage, thereby facilitating nonsurgical management, which is
the preferred option. Amphotericin B is the antifungal drug of
choice and should prove to be effective for mucormycosis. How-
ever, amphotericin B toxicity is well described, and the broncho-
scopic injection of amphotericin B could be used to treat the lesion
directly and thereby avoid potential systemic toxicity. Aerosolized
and intravenous amphotericin B preparations were also used suc-
cessfully as adjunctive therapy in the treatment of this patient. Our
results indicate the efficacy of bronchoscopic injection of ampho-
tericin B in the treatment of pulmonary mucormycosis.
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Figure 2. Photomicrograph of transbronchial lung biopsy specimen from right upper lobe. Hematoxylin and eosin
stain of biopsy specimen revealed druse of Mucor. Organisms appear as broad, nonseptate hyphae.
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